Insulet starts pivotal EVOLVE study for fully closed-loop Omnipod M: full analysis
Insulet has moved its next type 2 diabetes platform into pivotal testing, announcing that the first participant has been enrolled in EVOLVE, a randomized U.S. trial of the company’s investigational fully closed-loop Omnipod M system. The study is designed to evaluate a more automated insulin delivery model for adults with type 2 diabetes who use insulin, with Insulet positioning the system as a way to reduce day-to-day management burden for both patients and care teams. (investor.insulet.com)
The announcement builds on several years of work by Insulet to expand automated insulin delivery beyond type 1 diabetes. In 2024, the company reported positive SECURE-T2D pivotal results for Omnipod 5 in adults with type 2 diabetes, showing improvements in HbA1c, time in range, hyperglycemia, insulin dose, and diabetes distress in a 305-patient study across 21 U.S. sites. Omnipod 5 has since been cleared by the FDA for adults with type 2 diabetes, giving Insulet a commercial foothold in a population that historically has had limited access to automated insulin delivery tools. (investor.insulet.com)
What’s new here is the degree of automation Insulet is aiming for. According to the company, EVOLVE will enroll up to 350 adults ages 18 to 75 at as many as 40 U.S. centers, including people using basal-only or basal-bolus insulin regimens. Insulet received FDA investigational device exemption approval in March 2026. The company says the fully closed-loop design is intended to remove bolus dosing, mealtime announcements, and startup settings, which could make the system more practical for broader use, particularly outside endocrinology clinics. (investor.insulet.com)
That strategy follows encouraging feasibility data. In EVOLUTION 2, presented at ATTD 2026, Insulet reported average time in range of 68%, representing a 24-percentage-point improvement over standard injection therapy, without mealtime interactions. The company has said EVOLUTION 2 built on its earlier EVOLUTION 1 work, where participants improved time in range from 52% to 65% with minimal hypoglycemia, and used those findings to refine the algorithm before starting the pivotal program. Study investigator Martin de Bock said the results suggested high time in range could be achieved with a fully automated, easier-to-use system. (investor.insulet.com)
Industry context also matters. The American Diabetes Association said its 2026 Standards of Care removed certain treatment prerequisites before starting continuous subcutaneous insulin infusion or automated insulin delivery, signaling a more permissive stance toward broader use of these systems. Insulet has explicitly linked its type 2 strategy to that shift, while also arguing that adoption remains low relative to the estimated 5.5 million U.S. adults with type 2 diabetes who require insulin. The company said its U.S. type 2 prescriber base grew by more than 60% in 2025 to more than 6,500 clinicians. (diabetes.org)
Why it matters: For veterinary professionals, the relevance is less about direct clinical crossover and more about how chronic-disease technology evolves in real-world care. EVOLVE is a case study in where medtech is heading: fewer manual steps, lighter onboarding, broader use in primary care, and stronger emphasis on workflow fit. Those same pressures shape adoption of remote monitoring, connected therapeutics, and long-term management tools across animal health. At the same time, simplification doesn’t remove the need for vigilance. Insulet’s progress comes just weeks after the company initiated a March 12, 2026, voluntary correction for certain Omnipod 5 pods in the U.S., with the FDA later classifying it as a Class I recall tied to leakage-related dosing risk. (investor.insulet.com)
What to watch: The next milestones are enrollment progress, any presentation of the full EVOLVE protocol, and whether Insulet can hit its stated timeline of a 2027 510(k) submission and 2028 launch. It will also be worth watching whether regulators, clinicians, and payers view fully closed-loop use in insulin-treated type 2 diabetes as a meaningful expansion of access, or as a higher bar for evidence and post-market safety monitoring. That’s especially relevant as companies try to move advanced automation into larger, more heterogeneous patient populations. (investor.insulet.com)